Finance

Lists
Outlook: 70.0% bullish·0.0% bearish
Go to analysis
NAMS:NASDAQ
NewAmsterdam Pharma Company NV
$19.00
+0.53%
(+0.10) 1D
$19.00
0.00% (0.00)
After hours
Closed: Nov 9, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAMS...
Open
$19.08
High
$19.38
Low
$17.90
Mkt. cap
2.28B
Avg. vol.
1.52M
Volume
2.76M
52-wk high
$42.20
52-wk low
$17.90
EPS
-$1.68
Beta
0.14
Shares outstanding
119.93M
No. of employees
100
Open
$19.08
High
$19.38
Low
$17.90
Mkt. cap
2.28B
Avg. vol.
1.52M
Volume
2.76M
52-wk high
$42.20
52-wk low
$17.90
EPS
-$1.68
Beta
0.14
Shares outstanding
119.93M
No. of employees
100
News stories
From web sources and news partners
About NewAmsterdam Pharma Company NV
CEO-
Employees100
Founded2019
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenewamsterdampharma.com
Analyst ratings
Based on 10 analysts giving stock ratings to NAMS in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for NAMS in the last 3 months.
Highest
Current $19.00
$60.00 (+215.79%)
Average
$54.00 (+184.21%)
Lowest
$42.00 (+121.05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$60.00
+215.8%
11/09/2026
James Condulis
Stifel Nicolaus
Buy
Maintained
$50.00
+163.2%
11/09/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$52.00
+173.7%
11/06/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$57.00
+200%
11/05/2026
Conor MacKay
BMO Capital
Buy
Maintained
$58.00
+205.3%
11/05/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$42.00
+121.1%
11/04/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$55.00
+189.5%
11/05/2026
Geoff Meacham
Citi
Buy
Maintained
$55.00
+189.5%
10/15/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
$57.00
+200%
09/22/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
09/18/2026
Serge Belanger
Needham
Buy
Maintained
$48.00
+152.6%
08/07/2026
Unknown Analyst
Citi
Buy
Maintained
$55.00
+189.5%
08/06/2026
Evan Seigerman
BMO Capital
Buy
Initiated
$58.00
+205.3%
07/21/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$58.00
+205.3%
07/20/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$45.00
+136.8%
05/07/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/07/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$38.00
+100%
05/07/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$45.00
+136.8%
04/02/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
$49.00
+157.9%
02/19/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
32.00K
3.04M
3.70M
19.16M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38.59M
38.01M
41.67M
39.36M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.42M
23.45M
26.89M
24.00M
Operating expense
66.01M
61.46M
68.56M
63.35M
Total operating expenses
66.01M
61.46M
68.56M
63.35M
Operating income
-65.98M
-58.42M
-64.86M
-44.19M
Other non operating income
-15.34M
5.94M
-4.56M
23.12M
EBT including unusual items
-74.92M
-48.44M
-64.14M
-16.18M
EBT excluding unusual items
-74.92M
-48.44M
-64.14M
-16.18M
Income tax expense
-
-
-
1.21M
Effective tax rate
-
-
-
-7.46%
Other operating expenses
-
-
-
-
Net income
-74.92M
-48.44M
-64.14M
-17.39M
Net profit margin
-234,134.38%
-1,593.45%
-1,732.91%
-90.74%
Earnings per share
-
-
-
-
Interest and investment income
6.47M
5.65M
5.81M
5.19M
Interest expense
-
-
-
-
Net interest expenses
6.47M
5.65M
5.81M
5.19M
Depreciation and amortization charges
-
-
-
-
EBITDA
-65.92M
-58.36M
-64.80M
-44.12M
Gain or loss from assets sale
11.00K
12.00K
6.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps